STOCK TITAN
  1. Home
  2. Sec-filings
  3. HOWL
  4. [8-K] Werewolf Therapeutics, Inc. Reports Material Event

Werewolf Therapeutics (HOWL) sells early cancer platforms, keeps key trials

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Werewolf Therapeutics, Inc. (HOWL) entered into an asset purchase agreement with EMD Serono Research & Development Institute Inc. on August 14, 2026, selling pre-clinical technology comprising its INDUCER platform and its INDUKINE platform (excluding the WTX-124 and WTX-330 clinical development programs) as the Transferred Assets. Werewolf retains all rights needed to continue developing its WTX-124 and WTX-330 clinical programs.

As consideration, EMD agreed to pay Werewolf upfront cash of $28.0 million plus an additional $5.0 million upon completion of the technology transfer. The parties provided customary representations, warranties, indemnities and a non-competition covenant under which Werewolf will not exploit certain compounds directed to the same tumor targets as any Transferred Compound for 24 months after closing, subject to change-of-control exceptions. Concurrently, EMD granted Werewolf an exclusive license to certain Transferred Assets patents necessary to conduct clinical development for WTX-124 and WTX-330, and additional license rights to support Werewolf’s existing collaboration arrangements with Harpoon Therapeutics, Inc. and Jazz Pharmaceuticals Ireland Limited.

Positive

  • None.

Negative

  • None.

Filing Explained

The August 14 closing puts Werewolf’s sale of the INDUCER and INDUKINE pre-clinical technology in an executed state: EMD agreed to pay $28.0 million upfront and another $5.0 million when the technology transfer is completed, while Werewolf retains the rights needed for its WTX-124 and WTX-330 clinical programs.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Upfront consideration from EMD $28.0 million Cash payable to Werewolf as consideration for the Transferred Assets
Additional consideration upon technology transfer completion $5.0 million Contingent payment after completion of the transfer of Transferred Assets technology
Non-competition covenant term 24 months Period after Closing during which Werewolf will not exploit certain competing compounds
Asset Purchase Agreement closing date August 14, 2026 Date of Closing and execution of the Asset Purchase Agreement and License Agreement
Harpoon License date December 20, 2019 Date of Second Amended and Restated Assignment and License Agreement with Harpoon
Jazz Asset Purchase Agreement date May 7, 2026 Date of Asset Purchase Agreement between Werewolf and Jazz related to a separate license
Asset Sale financial
"the Company sold to EMD (the “Asset Sale”) technology comprising"
An asset sale is when a company sells specific pieces of its business—such as equipment, real estate, product lines, or patents—rather than selling ownership shares. Like selling a car from a household to raise cash without moving out of the house, an asset sale can provide funds, reduce costs, or signal a change in strategy; investors watch it because it directly affects a company’s cash, future revenue potential, and balance sheet strength.
non-competition covenant regulatory
"the Purchase Agreement contains a non-competition covenant pursuant to which"
exclusive license financial
"EMD granted the Company an exclusive license to certain patents included"
An exclusive license is a legal agreement that gives one party the sole right to use, make, sell or commercialize a product, technology, patent, or other intellectual property, while the owner keeps ultimate ownership. Think of it like leasing a unique tool to a single tenant: that tenant alone can profit from it for the license term. Investors care because exclusivity can create predictable revenue streams, affect competitive position, valuation, and the likelihood of future royalties or milestone payments.
Transferred Intellectual Property financial
"products or programs claimed in the Transferred Intellectual Property (as defined"
indemnify regulatory
"the Company and EMD will each indemnify the other for certain losses"
To indemnify means to promise to cover or reimburse someone for losses, costs, or legal claims that arise from a specified action or event. For investors, indemnification shifts potential financial risk—like a safety net or warranty—so a party that agrees to indemnify protects others from unexpected liabilities, which can affect a company’s future expenses, deal terms, and perceived investment risk.

FAQ

What major transaction did Werewolf Therapeutics (HOWL) announce on August 14, 2026?
Werewolf Therapeutics entered into an asset purchase agreement with EMD Serono Research & Development Institute Inc., selling its pre-clinical INDUCER platform and parts of its INDUKINE platform while retaining rights needed to continue clinical development of WTX-124 and WTX-330.

How much cash will Werewolf Therapeutics (HOWL) receive from the EMD asset sale?
Werewolf Therapeutics is entitled to $28.0 million in upfront consideration from EMD Serono and an additional $5.0 million upon completion of the transfer of the Transferred Assets technology, for potential total consideration of $33.0 million tied to this transaction.

What assets did Werewolf Therapeutics (HOWL) sell to EMD Serono?
Werewolf sold technology comprising its pre-clinical INDUCER platform and its INDUKINE platform, including related patents, know-how, pre-clinical compounds and certain intangible assets, while excluding and retaining the clinical development programs for WTX-124 and WTX-330.

How is Werewolf Therapeutics (HOWL) preserving its WTX-124 and WTX-330 programs?
Werewolf retains all rights necessary to continue developing WTX-124 and WTX-330 and entered into an exclusive license under certain patents within the Transferred Assets that enable it to exploit and perform clinical development programs for these two drug candidates.

What non-compete restrictions affect Werewolf Therapeutics (HOWL) after this asset sale?
Under a non-competition covenant, Werewolf agreed not to exploit certain compounds, products or programs claimed in the Transferred Intellectual Property that are directed to the same tumor target as any Transferred Compound for 24 months after closing, subject to customary exceptions for change of control transactions.

How do Harpoon and Jazz factor into Werewolf Therapeutics’ (HOWL) new license agreement?
Under the License Agreement, EMD granted Werewolf additional licenses that enable Werewolf to grant certain sublicenses to Harpoon Therapeutics, Inc. under the Harpoon License and to Jazz Pharmaceuticals Ireland Limited under an existing license agreement related to technology initially licensed from Harpoon.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
NASDAQ 0001785530 false 0001785530 2026-08-14 2026-08-14 0001785530 dei:FormerAddressMember 2026-08-14 2026-08-14
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2026

 

 

WEREWOLF THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40366   82-3523180

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

303 Wyman Street, Suite 300  
Waltham MA   02451
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 952-0555

200 Talcott Ave, 2nd Floor

Watertown, Massachusetts 02472

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   HOWL   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 
 

Item 1.01. Entry into a Material Definitive Agreement.

On August 14, 2026 (the “Closing”), Werewolf Therapeutics, Inc. (the “Company”) entered into an asset purchase agreement (the “Purchase Agreement”) with EMD Serono Research & Development Institute Inc. (“EMD”), pursuant to which, and subject to the terms and conditions thereof, the Company sold to EMD (the “Asset Sale”) technology comprising (i) its pre-clinical INDUCER platform, including all patents and know-how related thereto, pre-clinical compounds and related intangible assets, and (ii) its INDUKINE platform, including certain patents, certain know-how related thereto, and pre-clinical compounds, excluding the clinical development programs for WTX-124 and WTX-330 (collectively, the “Transferred Assets”). The Company retains all rights necessary for the continued development of its WTX-124 and WTX-330 clinical programs.

Pursuant to the Purchase Agreement and related ancillary agreements, in consideration for the Transferred Assets, EMD agreed to pay to the Company upfront consideration of $28.0 million and an additional $5.0 million upon the completion of the transfer of the Transferred Assets technology.

The Purchase Agreement contains customary representations, warranties and covenants of each of the Company and EMD. The Purchase Agreement further provides that, subject to certain limitations, the Company and EMD will each indemnify the other for certain losses arising from such breaches of representations, warranties and covenants and liabilities allocated to such party pursuant to the terms of the Purchase Agreement.

In addition, the Purchase Agreement contains a non-competition covenant pursuant to which the Company agreed not to exploit certain compounds, products or programs claimed in the Transferred Intellectual Property (as defined in the Purchase Agreement) that are directed to the same tumor target as any Transferred Compound (as defined in the Purchase Agreement) for a period of twenty-four (24) months after the Closing, subject to customary exceptions for change of control transactions.

The foregoing description of the terms of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the terms and conditions of the Purchase Agreement, a copy of which the Company intends to file with a subsequent Securities and Exchange Commission report.

Simultaneously with the execution of the Purchase Agreement, on August 14, 2026 the Company entered into a license agreement (the “License Agreement”) with EMD pursuant to which EMD granted the Company an exclusive license to certain patents included in the Transferred Assets that enable the Company to exploit and perform clinical development programs for WTX-124 and WTX-330.

Additionally, under the License Agreement, EMD granted to the Company certain licenses to enable the Company to grant certain licenses to (i) Harpoon Therapeutics, Inc. (“Harpoon”) under that certain Second Amended and Restated Assignment and License Agreement between the Company and Harpoon dated December 20, 2019 (the “Harpoon License”) and (ii) Jazz Pharmaceuticals Ireland Limited (“Jazz”) under the Company’s existing license agreement with Jazz that was entered into in connection with that certain Asset Purchase Agreement dated as of May 7, 2026 by and between the Company and Jazz, under which the Company has granted a non-exclusive license to certain technology originally licensed to the Company under the Harpoon License.

The foregoing description of the terms of the License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the License Agreement, a copy of which the Company intends to file with a subsequent Securities and Exchange Commission report.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    WEREWOLF THERAPEUTICS, INC.
Date: August 20, 2026     By:  

/s/ Daniel J. Hicklin

      Daniel J. Hicklin
      President, Chief Executive Officer and Director

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Other Documents